Physician profile
Mathias Lichterfeld
NPI 1578690921
$21,344.26
in general payments reported to CMS, 2019-2025
3 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2021: $750 · 2024: $6,184 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $2,143 · Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,545.00 |
| Travel and Lodging | $2,142.94 |
| Food and Beverage | $477.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10,831.75 | 2021-2025 | |
| Viiv Healthcare Company | $10,083.59 | 2024-2025 | |
| Gilead Sciences, INC. | $428.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathias Lichterfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.